BioSpace News Archive

Leveraging leading supply chain optimization and simulation technology to maximize the impact of nonprofit’s mission to restore sight and prevent blindness

Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein

Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy

Unisys Corporation (NYSE: UIS) today announced that the U.S. Department of Health and Human Services (HHS) has selected the company to compete for task and delivery orders under the Intelligent Automation/Artificial Intelligence (IAAI) contract.

Cardinal Health (NYSE: CAH) plans to release first quarter financial results for its fiscal year 2020 on Nov. 7 prior to the opening of trading on the New York Stock Exchange.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the Company’s preliminary proof of concept study results using its Rapid Acoustic Pulse (RAP)

Advanced BioScience Laboratories, Inc. (ABL), a global contract development and manufacturing organization for biotherapeutics and vaccines, announced today that the company was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health

Triumvira Immunologics (Triumvira), a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the issuance of key claims in U.S. Patent No. 10435453 entitled “Trifunctional T cell-antigen coupler and methods and uses thereof.”

MOBILion Systems, Inc., a life science company developing an analytical instrument platform that enables swift and precise drug discovery, development, and diagnosis for today’s complex diseases, has opened their new company headquarters in Chadds Ford, Pennsylvania

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders and filed a definitive consent statement with the Securities and Exchange Commission